ZB131
- Generic Name
- ZB131
- Drug Type
- Biotech
- Background
ZB131 is a monoclonal antibody with a high affinity and specificity for cancer-specific plectin (CSP), a cell surface protein identified in a wide range of cancers that correlates with poor prognosis and aggressive tumors.
A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors
Phase 1
Completed
- Conditions
- Solid Tumor, AdultBiliary Cancer MetastaticOvarian Serous AdenocarcinomaOvarian Serous CystadenocarcinomaPancreatic Ductal; Adenocarcinoma
- Interventions
- First Posted Date
- 2021-10-12
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- ZielBio, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT05074472
- Locations
- 🇺🇸
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇺🇸University of Virginia, Charlottesville, Virginia, United States
🇺🇸Mayo Clinic - Phoenix, Phoenix, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath